Silexion Therapeutics Corp — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Silexion dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center on September 30, 2026. Q3 2026 financings (public offering ~$2.5M, warrant inducement ~$0.84M, ATM ~$1.9M) increased cash to $4.8M and shareholders' equity to $3.0M as of September 30, 2026. New preclinical data showed immune-sensitization across four KRAS mutations and lipoprotein-mediated uptake mechanism; nine-month net loss was $8.8M.
Why this rating
Clinical trial activation and $5.2M financing are material relative to $4.2M total assets; however, going-concern doubt and 9-month $8.8M burn against $4.8M cash remaining create material near-term funding risk.
Tradability signal
NO TRADE
No trade: price $0.00 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.00 | +10 min · unknown $0.00 ▲ 0.00% | +30 min · unknown $0.00 ▲ 0.00% | +1 hr · unknown $0.00 ▲ 0.00% | +4 hrs · unknown $0.00 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.